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Abstract: In the post-genome era, high throughput gene expression profiling has been successfully used to develop 
genomic biomarker panels (GBP) that can be integrated into clinical decision making. The development of GBPs in the 
context of personalized medicine is a scientifically challenging and resource-intense process. It needs to be accomplished 
in a systematic phased approach to address biological variation related to a clinical phenotype (e.g. disease etiology, 
gender, etc.) and minimize technical variation (noise). Here we present the methodological aspects of GBP development 
based on the experience of the Cardiac Allograft Rejection Gene Expression Observation (CARGO) study, a study that 
lead to the development of a molecular classifier for rejection screening in heart transplant patients.  
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INTRODUCTION  
 The completion of the Human Genome Project has 
revolutionized the field of biomedical sciences by providing 
an answer to the question of the genetic sequence of the 
human species [1]. Based on this development, availability 
of high throughput whole genome gene expression profiling 
(GEP) technology has opened new horizons to understand 
the complex biology of systems [2]. Microarrays provide the 
ability to study the expression of thousands of known and 
unknown genes in samples from patients at times of specific 
clinical events. DNA microarrays [3-6] have been used to 
study gene expression patterns retrospectively in biopsies 
from normal and rejecting pediatric renal allografts [7] and 
have defined differential patterns of gene activation 
associated with rejection as well as nephrotoxicity. Gene 
expression profiling of peripheral blood mononuclear cells 
(PBMC), where circulating cells capture the deranged 
physiology of organ systems, has been successfully used to 
characterize the systemic inflammatory response following 
intravenous endotoxin administration in healthy individuals 
[8]. It has also been used to characterize multiorgan 
dysfunction (MOD) following trauma [9], to diagnose sepsis 
[10], and to characterize the response to mechanical 
circulatory support device surgery, with inflammatory 
activation and T-cell suppression in stable post-operative 
patients [11].  
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 Whole genome GEP technology has been successfully 
implemented to develop genomic classifiers to detect/predict 
outcomes in clinical medicine e.g. breast cancer [12,13], 
cardiac allograft rejection [14], and coronary artery disease 
[15,16]. In this article we will discuss the methodological 
aspects of genomic biomarker panel (GBP) development 
based on the experience of the Cardiac Allograft Rejection 
Gene Expression Observation (CARGO) study in the context 
of advancing post-genome era technology. We will use the 
exemplary phenotypes of heart transplant rejection (from our 
CARGO experience) and MOD (a challenging phenotype in 
our field of advanced heart failure) to elaborate the process 
of GBP development and validation. We will highlight the 
various challenges in the process and will suggest some 
possible solutions.  
SYSTEMS-BIOLOGICAL CONCEPTS IN MEDICINE 
 The strategic plan in gene expression biomarker panel 
development can best be conceptualized in the framework of 
systems biology. Systems biology is a comprehensive 
quantitative analysis utilized to understand in which way all 
the components of a biological unit interact functionally over 
time. Systems approaches have long been taken, particularly 
in immunology, physiology, development, and neurobiology. 
However, technology development during the 1980s 
permitted the concepts generated by many years of 
reductionist inquiry to be analyzed in the context of the 
entire system. Automated DNA sequencers enabled the 
sequencing of genomes and the definition of polymorphisms 
among individuals; microarray analysis permitted global 
transcriptional profiling [17], and advances in mass 
spectrometry led to large-scale proteomic and metabolomic 
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analysis. The plethora of data generated by these high-
throughput platforms led to the rapid growth of 
computational biology and bioinformatics. Thus, knowledge 
of the complete sequences of genomes, together with 
technology that permit the monitoring of information flow 
leading to specific cellular functions, set the stage for 
systems biology [18-39]. The NIH-roadmap explicitly 
incorporates this approach as a necessary future research 
strategy [40].  
 Systems biological approaches include level distinction 
(also termed multi-scaling), component interaction, emergent 
properties, downward causation, and dynamic “feedback 
loop” behavior. Emergent properties are properties which 
are present on higher levels of a system, e.g. heart transplant 
rejection or multi organ dysfunction [MOD], but cannot be 
monocausally explained by the properties of the individual 
components on a lower system level, (e.g. individual gene 
transcripts). Downward causation are effects of properties on 
higher levels of the system, e.g. rejection of the heart or 
MOD on the properties on a lower system level, (e.g. 
individual gene transcripts). Dynamic “feedback loop” 
behavior is the probabilistic effect of iterative interactions of 
systems components, e.g. a set of gene transcripts, on the 
properties of other systems components, e.g. MOD. In 
essence, the systems biological approach postulates that 
quantifiable differential expression patterns of individual 
genes, proteins, and modules on the molecular and cellular 
level are simultaneously related, in a mathematically 
describable probabilistic way, to the clinical entity of interest 
on the highest systems level, the phenotype level (Fig. 1). 
Within the concept of multiscaling of different hierarchical 
levels, the relationship between properties on the lower 
system level and emergent properties on the higher system 
level are key to understanding the phenotype within the 
concept of systems biology. 
 
Fig. (1). Systems biological perspective of relationship between 
genome, transcriptome, proteome, metabolome, and phenome. 
CONCEPTUAL CHALLENGES 
 The major challenge in clinical research and genomic 
biomarker panel development is to control for circumstances 
unrelated to the relationship between transcriptome and 
phenome level [41]. Standardized operational procedures are 
required to control for and minimize epidemiological, 
technical, biological/physiological, and statistical variation, 
which is unrelated to the outcome. This principle is applied 
to every step of experimental design, conduct, data analysis 
and interpretation. Another challenge to the validity of the 
findings relates to the number of samples to be included in a 
study. In 2005 Michiels et al. published a re-analysis of 
seven publically available microarray studies which all had 
the goal of cancer outcome prediction [42,43]. The authors 
showed that the list of genes identified as predictors of 
prognosis was highly unstable, and molecular signatures 
strongly depended on the sample numbers in the training 
sets. It highlights the primary challenge in using microarray 
data, where one is patient-limited and gene-rich: whether 
genes and signatures are truly significant or whether they are 
products of random variation (i.e. over-fitted to noise) [44]. 
The newer more cost effective microarray platforms have 
greatly helped to overcome the problems of over-fitting. For 
appropriate power calculation in gene expression studies the 
described methods need to be followed [38,45]. 
PHASED APPROACH 
 Based on a clinically important phenotype of interest, 
GEP based biomarker panel development is conducted in 
well defined phases (Fig. 2): (1) Clinical phenotype 
consensus definition; (2) Establishment of study logistics; (3) 
Candidate gene discovery using a combination of genome-
wide and knowledge-base approaches; (4) Differential gene 
list validation using PCR assays; (5) Molecular classifier 
algorithm development using rigorous statistical methods; 
and (6) External classifier validation in an independent 
patient population.  
Phase 1: Clinical Phenotype Consensus Definition 
 In medicine any clinical problem may elicit genomic test 
development. The consensus definition of the clinical 
phenotype of interest is critically important. Expectations 
toward a genomic test may include 1) identification of 
patients in the early stages of the development of the 
phenotype of interest, 2) differential diagnosis of the 
phenotype of interest from related phenotypes, 3) 
identification of patients at high risk for future development 
of a phenotype of interest, or 4) assessment of response to a 
specific therapy. 
Imperfect Clinical Phenotype Standards  
 Diagnostic test development requires a clinical standard 
against which to measure the new test’s performance. The 
existence of imperfect clinical standards creates a formidable 
challenge. For the correlation of clinical results with gene 
expression patterns it is crucial that the clinical phenotype is 
clearly defined. In the CARGO study the clinical standard 
was a biopsy-based histopathological assessment [14]. 
Biopsy sampling, however, is subject to sampling error, as 
technical procedures may vary from center to center and also 
from clinician to clinician. The ensuing histopathological 
assessment by a trained pathologist is subject to inter-
observer-variability [46]. The same was observed in the 
CARGO-study with concordance between core pathologists 
of 60% for moderate/sever rejection [47]. To minimize the 
impact of inter-observer and inter-center variability in 
genome
transcriptome
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determining the clinical phenotype, an approach with the 
panel of independent (“central”) investigators blinded to 
clinical information needs to be adopted for the appropriate 
selection of samples for gene expression studies. In analogy, 
to develop reliable phenotype comparators for the 
challenging phenotype of MOD, currently available best 
practice MOD-scoring systems [48-53] have to be utilized. 
 
Fig. (2). Approach to develop genomic diagnostic and prognostic 
classifiers/scores to detect/predict clinical outcomes divided into 1) 
phenotype definition, 2) establishment of study logistics, 3) gene 
discovery by microarray analysis, 4) differential gene list validation 
using RT-PCR, and 5) molecular classifier development using 
mathematical algorithm, and 6) external classifier validation in an 
independent patient population. 
Footnotes: MOD = presence of multiorgan dysfunction; No-MOD 
= absence of multiorgan dysfunction; SOP = standardized operating 
procedures; RT-PCR = real-time polymerase chain reaction. 
Dichotomous vs. Continuous Phenotype Choices  
Dichotomous phenotypes, typically with extreme ends of a 
clinical spectrum, with fully developed signs/symptoms on 
one end and a contrasting picture with no clinical 
signs/symptoms at the other end, are more likely to be 
associated with differential gene expression signatures and 
therefore are more appropriate choices for a proof-of-
principle study. Although for this proof-of principle rationale 
a design based on a dichotomous phenotype is preferable, the 
choice of a continuous phenotype spectrum may allow for a 
more practical outcome validation approach. In the 
phenotype of MOD where continuous scoring systems are 
used to grade the degree of organ dysfunction e.g. Sequential 
Organ Failure Assessment (SOFA) score [52,53], extreme 
scores can be used for the development of GBP to identify 
the right candidate genes associated with the disease. This 
GBP can be applied to assess the intermediate levels of 
organ dysfunction later on during validation. 
Static vs. Dynamic Phenotypes  
 Clinical disease phenotypes have historically been 
described as static entities by the presence or absence of 
characteristic clinical signs/symptoms and molecular 
markers of a disease process. While in fact the state of health 
and disease in human body is a dynamic phenomenon, static 
phenotype choices are relatively less challenging to assess 
the associated gene expression patterns. Characterizing the 
dynamics of a disease process in an organism is intrinsically 
more difficult than quantifications rooted in static features. 
One needs to assess and monitor the changes in a biological 
system over time using time series analysis of GEP.  
Phase 2: Establishment of Study Logistics 
 After the consensus definition of the – dichotomous or 
continuous – phenotype of interest, the establishment of 
multicenter study logistics is important especially in critical 
care medicine.  
Multicenter Study Design  
 A multicenter study design is recommended for genomic 
studies, it increases sample size but also variabilities. For 
example, in the CARGO-study, eight US-centers were 
involved.  
Standardized Operating Procedures  
 In general, sample processing and array analysis should 
be organized by consensus standardized operating 
procedures (SOP). Any SOP should be tested for validity in 
pilot studies (Fig. 3). Pilot or feasibility studies can be 
helpful in the early identification of problems in the 
collection, handling and processing of specimens before a 
larger study is undertaken. These pilot studies may also help 
in determining the new processes and personnel training 
needs required before the implementation of a new protocol. 
For example, the CARGO-study team paid clear attention 
that the clinical trial protocol addressed microarray-related 
aspects of sampling, sample processing and storage. The 
SOP was distributed to the participating centers and it 
required agreement upon by everyone involved, including 
clinicians and bioinformaticians. It specified in detail how 
biopsies should be taken and how blood should be drawn, 
including the tube type, storage temperature and storage 
duration. Only centers which agreed on these specifications 
were allowed to participate in the study. This process must 
take place well before the first sample is taken, and also 
include that each center is informed on the technologies that 
are applied to their samples [54].  
 For genomic studies, specimen collection protocols have 
special requirements for preservation of macromolecules 
and/or analytics of interest. In addition to specimen type, 
things to consider when planning to collect specimens 
include: the collection method, the collection tubes or 
containers needed, the population that will provide the 
specimen, personnel required to collect the specimen (and 
training in the collection process), the distance from the 
collection point to the processing lab and to the storage 
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facility (if this is a different location), stabilizing or 
preservation techniques for maintaining/preservation of 
macromolecules required for the specific analyses, and 
specimen labeling and tracking strategies.  
 
Fig. (3). Approach to develop consensus standardized operating 
procedures (SOP) for genomic studies including 1) development of 
initial protocol, 2) feasibility studies, 3) pilot studies, 4) problems 
identification, 5) troubleshooting, 6) protocol modification, 7) 
individual training, and 8) implementation of the new protocol. 
Whole Blood vs. PBMC Approach  
 Recently the whole blood approach was suggested which 
reduces the handling steps involved in sample processing but 
leads to contamination with Globin-mRNA from the RBCs 
which decreases transcript detection sensitivity and increases 
signal variation. Methods have been reported to reduce this 
contamination up to 70% [55] and gene expression platforms 
e.g. Affymetrix®, are available for improved array results 
using this approach. The comparative performance of these 
protocols still needs to be validated. If comparable results 
can be achieved, whole blood approach will be the best 
approach because of its advantage over the cell separation 
approach to minimize the technical noise.  
Core Microarray Facility  
 For microarray experiments samples need to be 
processed at a core microarray facility, which follows a 
specific SOP for each sample. Processing of all samples in 
batches, in a single microarray laboratory, ideally by one 
technician, limits the technical noise induced by handling of 
the samples by several individuals or by using different 
workstations in different laboratories. On the first level of 
clinical biomarker panel development one would like to 
avoid too much unwanted systematic technical noise.  
Phase 3: Candidate Gene Discovery 
 After establishing the multicenter infrastructure with 
motivated centers and established logistics for the sample 
processing the actual experimental phase of gene discovery 
is critical. 
Microarray Based Non-Supervised Approach  
 A variety of strategic decisions in the gene discovery 
process need to be made. The whole-genome wide approach 
provides more comprehensive scanning to identify 
significant and novel genes which were not described before 
in the clinical context of interest. Using different 
bioinformatics tools e.g. significance analysis of microarray 
(SAM), GeneSpringGX, and Partek, differentially expressed 
genes are identified in relationship to the concurrent 
phenotype of interest. 
Knowledge Based Approach  
 The knowledge-base approach, focusing on known 
genes, may ignore new biology which might be apparent in a 
non-hypothesis-driven approach. Although the knowledge-
based approach leads to the identification of genes that can 
distinguish the different phenotypes of interest, whole 
genome arrays may yield additional, different, or better gene 
candidates. 
 Both approaches can be combined with a leukocyte 
microarray and a knowledge-base approach or literature 
review as adopted in previous studies [13,14]. The goal is to 
find a set of genes that could be reproducibly measured by 
RT-PCR in an RNA preparation.  
Effect of Genetic Mutations  
 The presence of various genetic variations have effect on 
transcriptome [56]. The process and mechanisms of how 
these variations effect the gene expression is not well 
understood. One possible way to assess the effect of these 
variations i.e. gene deletion, gene duplication, single 
nucleotide polymorphism (SNP), and copy number 
variations (CNV) could be to assess their effect on the 
mRNA extracted and its detection by available techniques 
during gene discovery (Fig. 4). Through these effects on the 
transcriptome, these genetic variations can affect the results 
of not only gene discovery but also their validation and later 
clinical application of GBP. With the lack of current better 
understanding of the relationship between genetic variations 
and the transcriptome, it is difficult to address this  
challenge. 
 It has to be noted that in the GBP strategy proposed here, 
the emphasis is on assembly of expression profiling based 
candidate genes while purposefully neglecting the additional 
variation associated with various genetic variations on the 
genome level as well as the modulatory effect on the 
proteome level. 
Phase 4: Differential Gene List Validation/Verification 
Realtime-PCR Validations  
 Since the array-based non-supervised approach to 
discover differentially expressed genes is limited by 
sensitivity and variability, a second molecular biological 
method such as RT-PCR with higher sensitivity and lower 
variability needs to be applied to internally validate the 
discovery phase gene list. For realtime-PCR validation 
studies, genes which do not discriminate between absence 
and presence of the phenotype of interest are being 
considered as normalization genes. Additional assays should 
be included as controls to detect genomic DNA 
contamination by the difference between a transcribed and 
non-transcribed region of a gene e.g. the Gus-B gene and a 
spiked-in control template to determine if the PCR reaction 
was successful, e.g. the Arabidopsis gene [14].  
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 The differences observed between the microarray and 
PCR methods in significance of specific genes may be due to 
1) lower sensitivity of microarrays leading to the elimination 
of genes which show discrimination in PCR; 2) enhanced 
reproducibility of RT-PCR allowing measurement of small 
differences in gene expression [57], likely undetectable by 
microarrays (usually eliminating genes that show <1.5 - to 2-
fold changes). While a complete list validation by RT-PCR 
is the most complete approach, it is also the most resource 
intense approach. Based on the level of significance (false 
discovery rate (FDR) <0.05) and the available resources the 
gene list can be reduced to a small list for the external 
validation/testing studies. 
NanoString nCounter Gene Expression System  
 Recently digital mRNA quantification technology 
(NanoString nCounter analysis system) has been suggested 
to be a potential tool which does not require the enzymatic 
reactions as compared to real time PCR. This exciting new 
technology which currently is not using a whole 
transcriptome approach may be utilized for the validation 
step during classifier development instead of the RT-PCR 
approach after the initial gene discovery by array technology 
[58].  
Next Generation Sequencing 
 The next-generation sequencing (NGS), with direct 
sequencing and quantification of DNA and RNA, is opening 
new avenues for discovery in the post-genome era [59]. The 
technology is available as RNA-Seq for expression profiling. 
Currently, it has been shown to have comparable results with 
microarrays [60] and can be used for the gene discovery. 
Further developments in the technology may allow it as a 
future replacement for the RT-PCR as a new validation tool 
for the GBPs.  
Phase 5: Molecular Classifier Algorithm Development 
 The goal for the development of a diagnostic classifier is 
the systematic reduction of the internally validated 
differentially expressed gene list into a minimum number 
algorithm which then is subjected to external 
validation/training in Phase 6.  
Discriminatory vs. Classifier Genes  
 One must differentiate between the identification of 
discriminatory genes and the development of a robust 
classifier. For example in the CARGO-study, several 
cytotoxic T-cell genes were not selected for the classifier by 
the automated and unbiased statistical method of linear 
discriminant analysis, while PDCD1, a known marker of T 
cell activation, whose expression is correlated with the other 
T-cell genes was chosen in the final model. The fact that 
some of the “well-known” markers of this pathway were not 
selected by the method points to the strong relevance of 
PDCD1 as the optimal representative of this pathway and 
suggests that these other genes were either not incrementally 
informative or lacked sufficient reproducibility to be 
included in the model.  
Independent Testing of Selected Classifier Genes  
 To test the performance of the selected classifier genes, 
collected patient samples are typically randomly split into 
separate training and validation sets. The significantly 
differentially expressed genes identified in the training set 
and are tested in a validation set to estimate the degree of 
misclassification. Alternatively, the leave-one-out cross 
validation approach can be used which involves using a 
single observation from the original sample as the validation 
data, and the remaining observations as the training data. 
This is repeated such that each observation in the sample is 
used once as the validation data.  
Mathematical Modeling  
 The classifier score development poses unique 
mathematical modeling challenges. Conceptually, correlation 
strategies [61] and mutual information-strategies [62,63] 
need to be distinguished. The methods for analyzing gene 
expression data included principal components analysis, 
linear discriminant analysis (LDA, StatSoft Inc.), logistic 
regression (SAS Institute Inc.), Prediction Analysis of 
Microarrays (PAM), voting, classification and regression 
trees (TreeNet, Salford Systems), Random Forests, nearest 
shrunken centroids and k-nearest neighbors. LDA constructs 
a linear classifier by automatically selecting genes and/or 
metagenes [64] that, in combination, optimally separate 
 
Fig. (4). Effect of some basic types of genetic mutations on gene discovery in GBP development. 
Footnotes: SNP = single nucleotide polymorphism; CNV = copy number variation. 
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rejection and quiescent samples in the training set. The 
robustness of selected genes and the appropriate number of 
genes in the classifier were both evaluated by cross-
validation.  
Biological Plausibility of the Classifier/Test Gene List  
 An important challenge is in understanding how genomic 
results correlate to known or “expected” biological pathways 
for the disease state. Biological plausibility is a valid 
criterion to increase one’s confidence in a genomic result, 
but the converse—the lack of such information—is not 
evidence that a genomic result is false since the biological 
literature is not complete in this regard. In fact, genomic 
technologies enable researchers to discover new genes or 
pathways associated with disease that may not be expected 
from the existing literature. If only “expected” genes are 
accepted in genomics studies, new discovery will be stunted 
[14].  
Selection of Score Cutoff  
 After constructing the diagnostic test score with specific 
range using rigorous mathematical modeling (e.g. 0-40 for 
CARGO classifier) Receiver Operator Characteristic (ROC) 
curve analysis is performed to define the best possible cutoff 
on this range with desired sensitivity, specificity, negative 
predictive value (NPV), positive predictive value (PPV) in 
relationship to the phenotype of interest using Area Under 
the Curve (AUC) as a criteria to estimate how well the 
classifier performs. 
Phase 6: External Classifier Validation/Testing 
 The external clinical validation of the constructed 
diagnostic classifier in an independent patient sample is 
critically important in genomic test development.  
Independence of Primary Clinical Validation Cohort  
 After the initial training set of samples during the test 
development, it is mandatory to validate these results in an 
independent patient sample for the generalizability of the 
classifier performance. For example, in the CARGO-study, 
an independent cohort of CARGO patients was selected to 
validate the effectiveness of the LDA classifier defined in 
the Diagnostic Development phase using a prospective and 
blinded study protocol. The primary objective of the 
validation study was to test the prespecified hypothesis that 
the diagnostic score distinguishes absence of rejection, 
defined as ISHLT grade 0 from moderate/severe biopsy-
proven acute rejection, defined as ISHLT grade ≥3A, both 
grades determined from local and centralized cardio-
pathological examination. This was assessed using a two-
tailed Student’s t-test for comparing score distributions for 
rejection and quiescent samples. Secondary and exploratory 
objectives included documentation of diagnostic 
performance across thresholds and description of 
correlations to clinical variables.  
Clinical Test Replicability  
 In order to establish the test reproducibility and to 
demonstrate acceptable precision of the Test results further 
studies need to be designed to study the effect of different 
variables associated with the specimen handling process 
which may cause variation in test results e.g. operator-to-
operator variation, run-to-run variation, lot-to-lot variation of 
reagents, plate-to-plate variation, and section-to-section 
variation of the plates used to run the test.  
COMPARISON AGAINST STANDARD OF CARE & 
PERSONALIZED USE  
 While in the first step after GBP development, test 
performance should be based on cross-sectional phenotype 
identification by the GEP-test [65], in a second step required 
for full clinical acceptance [66], the GBP can be tested 
against the standard of clinical care e.g. endomyocardial 
biopsy (EMB) for heart transplant rejection monitoring. For 
heart transplant rejection monitoring, this comparison was 
performed between invasive EMB approach and the non-
invasive GBP approach in the Invasive Monitoring 
Attenuation through Gene Expression (IMAGE) trial. The 
results showed that the GBP monitoring approach lead to a 
significant reduction in the number of invasive biopsies and 
increased patient satisfaction in a low risk heart transplant 
patient population [67,68].  
 In the last step, the added information derived from intra-
individual temporal/longitudinal profiling increase the values 
of rule out, detection or prediction goals [69] and allows to 
enter into the personalized approach as compared to 
population based clinical scoring systems. In a case report 
we have described the existence of such a relationship 
between the heart transplant GBP and the organ level 
functions [70]. 
CONCLUSIONS 
 The scientific advancements in the post human genome 
project era have revolutionized the field of biomedical 
sciences. Using the available GEP technology has been 
successfully used to develop biomarker panels for different 
phenotypes in clinical medicine. The process of GBP 
development is associated with various conceptual, clinical, 
methodological, and computational challenges. These 
challenges in the GBP development can be best addressed by 
adopting the described novel systematic phased approach.  
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